EAN 2021 | Benefits of SC natalizumab in MS

Bart Van Wijmeersch, MD, PhD, Rehabilitation and MS Center Overpelt & University of Hasselt, Hasselt, Belgium, outlines the potential benefits of subcutaneous (SC) injection of natalizumab compared to intravenous (IV) infusion in the treatment of multiple sclerosis (MS). From a patients’ perspective, the SC formulation offers increased flexibility, convenience, and reduced time in a hospital setting. Furthermore, the reduced administration time and related costs increase the efficiency of the healthcare system. Prof. Van Wijmeersch explores the practicalities for switching or starting SC natalizumab. More data on IV and SC natalizumab from the NOVA trial (NCT03689972) will be available in the following months. This interview took place during the European Academy of Neurology 2021 congress.